Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond

The recent FDA approval of the neurosteroid, brexanolone (allopregnanolone), as a treatment for women with postpartum depression, and successful trials of a related neuroactive steroid, SGE-217, for men and women with major depressive disorder offer the hope of a new era in treating mood and anxiety...

Descripción completa

Detalles Bibliográficos
Autores principales: Zorumski, Charles F., Paul, Steven M., Covey, Douglas F., Mennerick, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Articles from the Special Issue on Allopregnanolone role in the neurobiology of stress and mood disorders; Edited by Graziano Pinna
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804800/
https://www.ncbi.nlm.nih.gov/pubmed/31649968
http://dx.doi.org/10.1016/j.ynstr.2019.100196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804800/
https://www.ncbi.nlm.nih.gov/pubmed/31649968
http://dx.doi.org/10.1016/j.ynstr.2019.100196

Ejemplares similares